Date: 2011-04-19
Type of information: Fundraising
Company: Circassia (UK)
Investors: Imperial Innovations (UK) - other existing shareholders, including Invesco Perpetual
Amount: £60 Million (€67 million - $98 Million)
Funding type: fundraising
Planned used: The new investment will fund phase III development programmes for Circassia\'s cat and ragweed allergy therapies. The financing will also fund the completion of phase II testing of the company\'s house dust mite and grass allergy T-cell vaccines, and will advance the development programmes for three additional allergy therapies and Circassia\'s recently acquired psoriasis treatment, PAP-1 (see http://biopharmanalyses.fr/agreements/?pageid=619).
Others: Circassia Ltd, a specialty biopharmaceutical company focused on allergy, has closed a £60 million ($98 million) fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual. The investment, which is scheduled in two tranches over the next two years, is the second largest fundraising by a privately-held European biopharmaceutical company this year, and the third largest in more than 15 years. To date, Circassia has successfully completed four investment rounds, raising approximately £93 million ($159 million).
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
